anamorelin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
growth hormone release-stimulating peptides	5487	861998-00-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: anamorelin anamorelin hydrochloride adlumiz ONO-7643 ST-1291 RC-1291	Anamorelin is a potent and selective novel ghrelin receptor agonist that mimics the N-terminal active core of ghrelin. ANAM stimulates neuroendocrine responses and can induce rapid positive effects on appetite and metabolism, which can lead to an increase in body weight and lean body mass. Molecular weight: 546.72 Formula: C31H42N6O3 CLOGP: 2.80 LIPINSKI: 1 HAC: 9 HDO: 3 TPSA: 114.77 ALOGS: -4.72 ROTB: 9

Molecule

Description

Molfile Inchi Smiles

Synonyms:

anamorelin
anamorelin hydrochloride
adlumiz
ONO-7643
ST-1291
RC-1291

Anamorelin is a potent and selective novel ghrelin receptor agonist that mimics the N-terminal active core of ghrelin. ANAM stimulates neuroendocrine responses and can induce rapid positive effects on appetite and metabolism, which can lead to an increase in body weight and lean body mass.

Molecular weight: 546.72
Formula: C31H42N6O3
CLOGP: 2.80
LIPINSKI: 1
HAC: 9
HDO: 3
TPSA: 114.77
ALOGS: -4.72
ROTB: 9

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Jan. 22, 2021	PMDA	ONO PHARMACEUTICAL Co., Ltd

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	97.00	49.68	29	209	135961	79608189

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

None

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Cancer cachexia	indication	788876001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Growth hormone secretagogue receptor type 1	GPCR	Q92847	GHSR_HUMAN	AGONIST	IC50	8.14		DRUG LABEL	DRUG LABEL

External reference:

ID	Source
249921-19-5	SECONDARY_CAS_RN
CHEMBL2110579	ChEMBL_ID
C000593861	MESH_SUPPLEMENTAL_RECORD_UI
C524461	MESH_SUPPLEMENTAL_RECORD_UI
DB06645	DRUGBANK_ID
D08856	KEGG_DRUG
C2698934	UMLSCUI
CHEMBL2103794	ChEMBL_ID
8846	INN_ID
9828911	PUBCHEM_CID
DD5RBA1NKF	UNII

Pharmaceutical products:

None